Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
23.70%
Operating Margin
21.29%
Net Margin
12.67%
Efficiency Metrics
Revenue per Expense Ratio
1.27
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
39.74%
Income Tax Rate
0.48%
EPS
0.5600000000
Balance Sheet Analysis
Current Ratio
1.23
Cash Ratio
0.52
Working Capital
$52.73M
Debt to Equity
0.76
Debt to Assets
42.13%
Equity Ratio
55.08%
Cash Flow Analysis
Operating Cash Flow Ratio
30.07%
Free Cash Flow Ratio
-23.84%
CapEx to Revenue
53.91%
Dividends Paid
$100.02M
Stock Buybacks
$8.36M
Total Shareholder Returns
$108.38M
Cash Position Change
-14.08%
Key Takeaways (2023 FY)
Revenue declined by 20.448854736963%, indicating potential market challenges
Detailed Growth Metrics
Core Performance
Revenue
-20.45%
Net Income
-75.69%
EPS
-75.65%
Operating Income
-56.65%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
-8.32%
Operating Cash Flow
-47.09%
Free Cash Flow
-147.75%
Balance Sheet Health
Assets
7.11%
Debt
18.02%
Book Value per Share
0.64%
Inventory
-10.01%
Shareholder Returns
Dividends per Share
-78.71%
Shares Outstanding
-0.38%
Long Term Trends
3Y Revenue/Share
4.63%
5Y Revenue/Share
-2.67%
3Y Dividend/Share
902.58%
5Y Dividend/Share
11.09%